# Neogenomics (NEO) — News

NEO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/neo/news

## Recent headlines

- [Neogenomics expands Indica Labs partnership to scale AI-powered digital pathology](https://www.ainvest.com/news/neogenomics-expands-indica-labs-partnership-scale-ai-powered-digital-pathology-2610) — AInvest Wire, Oct 15, 2026
  Neogenomics, a leader in next-generation sequencing and advanced diagnostic testing, has expanded its collaboration with Indica Labs, a global provider of AI-powered digital pathology software. The partnership aims to enhance the integration of AI-driven diagnostic tools into Neogenomics’ pathology…
- [Neogenomics, Inc.: Needham raises target price to $22 from $19](https://www.ainvest.com/news/neogenomics-needham-raises-target-price-22-19-2610) — AInvest Wire, Oct 6, 2026
  Needham & Company has raised its price target for NeoGenomics (NASDAQ:NEO) to $22 from $19, while maintaining its Buy rating for the stock. This adjustment reflects the firm’s continued confidence in the company’s growth prospects and operational performance. The updated target represents one of…
- [Nebogenomics, Inc.: BTIG raises to buy from neutral](https://www.ainvest.com/news/nebogenomics-btig-raises-buy-neutral-2610) — AInvest Wire, Oct 6, 2026
  On October 5, 2026, BTIG upgraded NeoGenomics, Inc. (NEO) to "Buy" from "Neutral," setting a price target of $28 per share. This move follows a series of recent developments, including the appointment of Warren Stone as the company’s next CEO and the release of Q3 revenue guidance . The stock has…
- [Nogenomics, Inc.: Stonex raises target price to $20 from $16](https://www.ainvest.com/news/nogenomics-stonex-raises-target-price-20-16-2610) — AInvest Wire, Oct 6, 2026
  Stonex has raised its price target for NeoGenomics, Inc. (NEO) to $20 from $16, reflecting a positive outlook on the cancer diagnostics company’s recent developments and strategic initiatives. This adjustment aligns with several recent analyst upgrades and maintains the firm’s "Buy" rating for the…
- [Neogenomics down 4.1% after prelim. results, new CEO named](https://www.ainvest.com/news/neogenomics-4-1-prelim-results-ceo-named-2610) — AInvest Wire, Oct 5, 2026
  NeoGenomics Inc. (NG9.MU) shares fell 4.1% in early trading on October 5, 2026, following the release of preliminary financial results and the announcement of a new chief executive officer. The company reported Q1 2026 revenue of $186.7 million, reflecting an 11% year-over-year increase and…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).